New treatments for amyloidosisAn anti-CD38 monoclonal antibody and an in vivo gene-editing approach show promise for the treatment of different forms of systemic amyloidosis in separate clinical trials.doi:10.1038/s41584-021-00680-5Sarah OnuoraNature Reviews Rheumatology...
This is an exciting time for the AL amyloidosis community as patient advocacy groups, academia, pharmaceutical companies, and regulatory agencies are joining in an effort to develop safe and effective treatments for patients with AL amyloidosis. Clinical research efforts in AL amyloidosis have focused ...
Whether the ultimate outcome of future research will be a single-treatment solution for all patients, or whether treatments will become better-tailored to the individual (based on prognostic markers and pre-existing co-morbidities) has yet to be determined. 展开 ...
we describe the epidemiology, clinical diagnosis, pathogenesis, mechanisms and therapies of autoimmune diseases. We provide a timeline to summarize the significant advances in the field of antigen-specific immunotherapy for the treatment of autoimmune diseases. We describe ...
It provides clinically important information which is not otherwise available, makes a valuable contribution to patient management and should assist in the assessment of existing and novel treatments for amyloidosis.doi:10.1007/978-94-011-3284-8_187M. B. Pepys...
Voquezna triple pak (amoxicillin, clarithromycin, and vonoprazan fumarate) and Voquezna double pak (amoxicillin and vonoprazan fumarate). Both products are to treat H. Pylori infections in adults. Phathom Pharmaceuticals focuses on developing and commercializing new treatments for gastroin...
for the treatment of Sickle Cell Disease [26]. Additionally, CRISPR-Cas9 is being evaluated for in vivo delivery using mRNA-LNP system, with treating transthyretin amyloidosis initiated in 2021 [27]. In Fig.1A, mRNA technology is contextualized among other innovative therapeutic modalities for ...
It is important to note that ferroptosis has also been closely linked to resistance to various cancer treatments. For example, several studies found that cancer cells with a high-mesenchymal state are more resistant to a variety of cancer treatments, but are particularly susceptible to ferroptosis-...
metal dyshomeostasis is closely linked to various events in AD such as amyloidosis, tauopathy, oxidative stress, and neuronal death. This hypothesis provides an alternative approach to understanding the pathogenesis of AD and detecting pathological changes. Further research is necessary to elucidate its...
The Aβ hypothesis is the mainstream hypothesis for the pathogenesis of AD and has influenced the direction of drug development over the past three decades. According to the hypothesis, the pathological progression of AD originates from asymptomatic cerebral amyloidosis many years before the onset of...